Combination Products: Regulatory Challenges and Successful Product Development

Front Cover
CRC Press, Apr 22, 2008 - Medical - 264 pages
The field of combination product development (products born of the integration of medical devices, biologics, and drugs) is so new that, while literature abounds on each part individually, there are very few publications, including FDA documents, available concerning the unique challenges posed by this nascent but fast-growing area.
Providing the first in-depth look at this breakthrough field, Combination Products includes practical guidelines and a detailed step-by-step process for the development of these novel technologies. It addresses the technical, scientific, regulatory, and quality issues that arise when combining drugs, biologics, and medical devices into a single product. It takes a practical, readily applicable approach to discussing the challenges, victories, and pitfalls associated with merging technologies and systems and how to implement these products into the market successfully and in a timely manner.
Specifically, this text explores the process from start to finish, establishing a workable design and development plan complete with relevant definitions. It reviews FDA and other regulatory expectations and covers resource requirements, manufacturing pitfalls, post-launch compliance requirements, and agency audits and challenges.
Drawing on the experience and expertise of two leaders in their respective fields, Combination Products boasts the credentials of Dr. Smita Gopalaswamy, a 20 year veteran of technical consulting responsibilities in medical device, biologics, and pharmaceutical industries as well as combination products, along with the support of Dr. Venky Gopalaswamy, an expert in business improvement methodologies such as six sigma, lean, and change management, to provide a comprehensive assessment of the field and an efficient and effective approach to the creation and implementation of combination products.

What people are saying - Write a review

User Review - Flag as inappropriate

On page 75 of the book it is wrongly written that Vitagel was regulated by CBER. The product was regulated by CDRH.


chapter two Overview of combination products
chapter three Ensuring successful combination product development
chapter four Overview of FDA and other regulatory agency expectations
chapter five Resource requirements
chapter six Manufacturing of combination products
chapter seven Challenges and pitfalls to avoid with combination products
chapter eight Postlaunch compliance requirements
chapter nine Agency audits and challenges
chapter ten Conclusions
Back cover

Other editions - View all

Common terms and phrases

Popular passages

Page 19 - State or. possession, any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, or arsphenamine or its derivatives (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of diseases or injuries of man...
Page 16 - A product comprised of two or more regulated components, ie, drug/ device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; (2) Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; (3) A drug, device, or biological product packaged separately that according to...

Bibliographic information